Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Immune-phenotyping of Surgically Resected HCC Following Neoadjuvant and Adjuvant Treatment With MK-3475

NCT04224480 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT04224480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04224480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Immune-phenotyping of Surgically Resected HCC Following Neoadjuvant and Adjuvant Treatment With MK-3475
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 1
Overall status
Unknown status
Start date
December 10, 2019
Completion date
December 31, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma